{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:13:10Z","timestamp":1785906790959,"version":"3.56.0"},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Botulinum neurotoxin type A (BoNT\u2010A) is well\u2010established for treatment of glabellar lines (GLs), and mostly formulated as powders requiring reconstitution for injection. The approved liquid formulation, ready\u2010to\u2010use (RTU) abobotulinumtoxinA was developed to ease injection procedures and prevent reconstitution errors. This multicenter, open\u2010label, Phase IV study evaluated GL treatment experience using RTU abobotulinumtoxinA versus powder BoNT\u2010A (onabotulinumtoxinA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Females with experience of BoNT\u2010A facial treatment were randomized 2:1 to GL treatment with 50\u2009U RTU abobotulinumtoxinA (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200999) or 20\u2009U powder BoNT\u2010A (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200951) and followed\u2010up for 6\u2009months or 1\u2009month, respectively. Assessments included: time to prepare each product for injection (primary endpoint); investigators' experience with product preparation\/reconstitution; investigators' and subjects' treatment experience; safety; and for the RTU product: aesthetic improvement of GLs; subject satisfaction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared with powder BoNT\u2010A, RTU abobotulinumtoxinA required statistically significantly less preparation time (mean 0:33 vs. 1:34\u2009min: s;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Investigators preferred RTU abobotulinumtoxinA over powder BoNT\u2010A (81% of treatment sessions) and found it allowed more time to communicate with subjects (97%). All investigators (100%) also found it easy\u2010to\u2010use, easy\u2010to\u2010learn, and that it fulfilled their expectations. Subjects found the RTU abobotulinumtoxinA treatment comfortable (91%), and through 6\u2009months posttreatment, most reported satisfaction with their appearance (\u226588%), looking natural (\u226595%) and refreshed (\u226580%). At Month 1, 99% of RTU\u2010treated subjects had investigator\u2010assessed improved aesthetic appearance in GLs, maintained in 76% at Month 6. No serious adverse events occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RTU abobotulinumtoxinA for GL treatment is well\u2010tolerated, efficacious, shows high levels of subject satisfaction throughout 6\u2009months, saves time, and is preferred by clinicians over powder BoNT\u2010A.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov Registry<\/jats:title>\n                    <jats:p>NCT05277337.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jocd.16359","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T02:59:45Z","timestamp":1716951585000},"page":"2857-2866","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ready\u2010to\u2010use abobotulinumtoxinA solution versus powder botulinumtoxinA for treatment of glabellar lines: Investigators' and subjects' experience in a Phase IV study"],"prefix":"10.1111","volume":"23","author":[{"given":"Priyanka","family":"Chadha","sequence":"first","affiliation":[{"name":"Acquisition Aesthetics London &amp; Cavendish Clinic  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Arne","family":"Gerber","sequence":"additional","affiliation":[{"name":"Dermatologie am Luegplatz and Medical Faculty Heinrich\u2010Heine\u2010University  D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Hilton","sequence":"additional","affiliation":[{"name":"Studienzentrum Privatpraxis Dr. Hilton &amp; Partner  D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Molina","sequence":"additional","affiliation":[{"name":"Medikas Clinic Medikas Medispa Ltd  Street UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Haq","sequence":"additional","affiliation":[{"name":"Haq Medical Consultancy and AM Aesthetics  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Partridge","sequence":"additional","affiliation":[{"name":"The Aesthetic Consultancy  Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Wong","sequence":"additional","affiliation":[{"name":"Vindoc Aesthetics  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"University Bochum Klinikum der Ruhr Universitaet Bochum; Hautklinik aesthetisch\u2010operative Medizin  Bochum Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Persson","sequence":"additional","affiliation":[{"name":"Galderma  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Prygova","sequence":"additional","affiliation":[{"name":"Galderma  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S9338"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.prs.0000475758.63709.23"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001330"},{"issue":"2","key":"e_1_2_12_5_1","first-page":"31","article-title":"Comparison and overview of currently available neurotoxins","volume":"7","author":"Walker TJ","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dsu.12100"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.121356"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dsu.12160"},{"issue":"7","key":"e_1_2_12_9_1","first-page":"776","article-title":"Efficacy of incobotulinumtoxinA for treatment of glabellar frown lines: a post hoc pooled analysis of 2 randomized, placebo\u2010controlled, phase 3 trials","volume":"40","author":"Jones D","year":"2014","journal-title":"Dermatologic Surg"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e3181b5641b"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archfaci.2009.5"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03475.x"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dsu.12008"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dsu.12404"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/PSN.0000000000000121"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-12-60"},{"issue":"6","key":"e_1_2_12_17_1","first-page":"735","article-title":"Incorrect reconstitution of incobotulinumtoxinA leads to loss of neurotoxin","volume":"13","author":"Carey WD","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_12_18_1","unstructured":"Galderma.Alluzience EU SmPC.https:\/\/www.medicines.org.uk\/emc\/product\/13798\/smpc"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000003594"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjz248"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjz003"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00951-x"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjab329"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjw272"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.asj.2009.09.003"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjw282"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.16359","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jocd.16359","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.16359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T06:56:40Z","timestamp":1778914600000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.16359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/jocd.16359"],"URL":"https:\/\/doi.org\/10.1111\/jocd.16359","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"2024-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}